MedTech

The MedTech sector is evolving at an unprecedented pace, driven by the convergence of engineering, software, artificial intelligence, digital health and bioinformatics.

This shift is transforming how the industry diagnoses, treats, and cares for patients, but it also introduces complexity, especially when it comes to protecting Intellectual Property (IP).

At HGF, we work with industry-leading companies across the sector to develop agile, robust IP strategies. Whether you are developing a life-saving implant, a connected monitoring device, or a next-generation diagnostic system, our multidisciplinary team combines deep sector knowledge with technical expertise across engineering, digital health, bioinformatics, and materials science.

We act as an extension of your in-house team, leveraging deep sector insight with legal precision. With experts across a range of jurisdictions and technical fields, we offer full-spectrum IP support tailored to the fast-evolving demands of MedTech innovation.

Latest news

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

The concept of ‘overall impression’ in UK and EU Registered Design Law

 

Read article

The Antibody Series #2 | Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our medtech specialists.